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Opioid overdose is one of the leading health problems in the United States. Since 1999, 
deaths from drug overdose in the United States have more than doubled. The development of 
public policies to provide naloxone to the public is crucial in mitigating some of the negative 
effects of opioid substance abuse. Current economic literature has primarily focused on the 
relationship between naloxone access laws and opioid overdoses. In this paper, I use a 
multinomial logit regression to examine the impact of passing a naloxone access law on the type 
of referrals and admin treatment settings of drug treatment center for opioid abuse. I measure 
referral source and service setting at admission to publicly funded drug treatment centers using 
the Treatment Episodes Data Set (TEDS) from 1999 to 2015 and use information on naloxone 
access laws from the Policy Surveillance Program (PSP). I find that when a naloxone access law 
is enacted, the probability of a community referral, relative to an individual referral, increases by 
37.5% while the probability of a detox setting at admission relative to an ambulatory setting 
decreases by 49.9%. When a third-party provision is enacted, the probability of a community 
referral relative to an individual referral increases by 39.4%. If there is a criminal liability 
provision enacted, the probability of a criminal/court referral, relative to an individual referral, 
increases by 24.6%. If there is a civil liability provision, the probability of a community referral, 
relative to an individual referral increases by 28.4% and the probability of a detox setting at 
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Since 1999, drug overdose deaths in the United States have more than doubled (Chen, et 
al. 2015). Drug overdoses are now the leading cause of injury death in the U.S., surpassing both 
traffic accidents and gun-related deaths. The opioid epidemic has swept through the U.S. and has 
been affecting people from all walks of life; ranging from the homeless to the top 2%.  
In an effort to deal with the growing opioid epidemic throughout the country, all states, 
along with the District of Columbia and Puerto Rico1 have passed variations of the Naloxone 
Access Law (NAL), allowing laypersons to administer naloxone hydrochloride (naloxone), an 
opioid receptor, to a person experiencing an overdose. The first state to pass such a law was New 
Mexico in 2001, with other states quickly following suit. Some states have even issued a 
standing order allowing pharmacists to dispense naloxone to people without a prescription (Non-
Prescription Standing Order).  
Naloxone programs have generally been supported by medical professionals and 
lawmakers from both political parties. However, there are critics (Dolac and Mukherjee 2019) 
who believe that easy access to naloxone could unintentionally increase opioid abuse by saving 
the lives of active drug users who will then continue to abuse opioids. The belief is that it will 
reduce the risk per use and will make opioid use more appealing. In April of 2016, Governor 
LePage of Maine vetoed a Non-Prescription Standing Order, stating that “naloxone does not 
truly save lives; it merely extends them until the next overdose” (Newman 2016). His veto was 
later overturned by the Maine legislature. Researchers have actually found that the adoption of a 
NAL is associated with a 9 to 11 percent reduction in opioid-related deaths (Rees 2017), 
 
1 Puerto Rico has been excluded from this study 
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Naloxone has been inexpensively available since 1985, but over the past few years, the 
growing demand has led to an increase in price. Currently, the price of naloxone hovers around 
$20-$40 for the generic option, but prices continue to rise (Newman 2016). This could present a 
barrier to those seeking the life-saving drug. If the price of naloxone continues to increase, 
limiting the accessibility to the general public, there is a possibility that it will not be as effective 
in reducing opioid related deaths and potentially deter treatment admission.  
In this paper I estimate the effect of NALs on the type of referrals and treatment setting at 
admission at a publicly funded treatment center for opioid abuse. The purpose of this study is not 
to find out if passing a naloxone access law and the provisions increase or decrease admissions to 
treatment centers, but to see if these laws change the types of referrals and settings for people 
admitted to treatment centers. I use a maximum likelihood (polytomous) logit regression and 
data from the Treatment Episode Data Set and the Policy Surveillance Program.  
I find that when a state passes a Naloxone Access Law, this increases the probability of a 
community referral relative to an individual referral by 37.5%. Adding a third-party provision 
increases the probability of a community referral relative to an individual referral by 39.4%. 
Adding a civil liability provision, increases the probability of a community referral relative to an 
individual referral by 28.4%. These increases are likely due to the fact that naloxone is more 
accessible to organizations or groups that can easily identify people at risk of overdoses (shelters, 
Narcotics Anonymous, etc.). Now that they are able to get a hold of naloxone and are free from 
any criminal prosecution for administering naloxone, they can help prevent potential overdose 
deaths and urge those people to seek treatment.  
Enacting a provision for criminal liability increases the probability of a criminal/court 
referral, relative to an individual referral, by 24.6%. Without fear of legal consequences, lay 
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administrators are more likely to call emergency responders after administering naloxone to a 
person experiencing an overdose. This gives the victim more chance of getting treatment through 
referral from a criminal or court system. 
When a naloxone access law is put into effect, the probability of a detox setting at 
admission relative to an ambulatory setting decreases by 49.9%.  When there is a civil liability 
provision, the probability of a detox setting at admission relative to an ambulatory setting 
decreases by 54.5%. These changes are likely due to the fact that more administrations are 
happening outside of medical offices are people are not entering treatment centers for detox.  
2. Background 
Since 2001, a number of cities and states in the United States have initiated other 
programs and/or policies in combination with NALs to combat the opioid epidemic. Many states 
have prescription drug monitoring programs (PDMPs) to improve opioid prescribing and protect 
patients at risk. PDMPs collect information on all filled prescriptions for controlled substances to 
identify and deter drug abuse and identify persons addicted to prescription drugs. There is strong 
evidence that PDMPs lead to a reduction in opioid prescribing by physicians (Bao, et al., 2016). 
As noted above, all states, the District of Columbia and Puerto Rico have passed some 
version of a NAL. Naloxone reverses the potentially fatal respiratory depression caused by 
heroin and other opioids and can be administered via intramuscular, intranasal, intravenous, or 
subcutaneous routes (Heller, et al., 2007). It has no agonist properties and therefore cannot be 
abused and has minimal potential for misuse.  
Some states have allowed naloxone to be prescribed to third parties – people who might 
witness an overdose, including friends and family of people who use drugs. Most overdoses are 
witnessed by others (Tracy, et al., 2005) and more accessibility to naloxone gives witnesses the 
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opportunity to take on the role of a responder. Naloxone can be administered with little to no 
formal training (Wheeler, et al., 2015), is safe to use, and is a cost-effective method of reducing 
overdose deaths. The side effects of naloxone are minimal and include headache, nausea, 
sweating and vomiting, none of which are life threatening (Boyer, 2012). If administered timely, 
it can reverse the effects of the overdose and gives the administrator and/or victim time to call 
trained professionals. 
2.1. Related Literature 
This paper contributes to a growing literature on policies that address the opioid 
epidemic. Researchers have examined the impact of various policies and programs like 
prescription drug monitoring programs (Dave, et. al., 2017) and access to opioid antagonists like 
naloxone on opioid abuse (Rees, et. al., 2017).  
The ongoing opioid epidemic can be, in part, explained by an increase in prescription 
drug misuse. Over 50 million individuals aged 12 and over have misused2 prescription drugs in 
their lifetime (Dave, et. al., 2017). A study done by Schnell, et. al. found that within the same 
specialty and practice location, physicians who completed their initial training at top medical 
schools were writing significantly fewer opioid prescriptions annually compared to physicians 
from lower ranked schools. States have tried to put more control on opioid prescribing with 
PDMPs.  
Dave et. al., 2017 estimates the impact of PDMPs on prescription drug abuse, using 
substance abuse treatment admissions as a measure of abuse. They use the Treatment Episode 
Data Set from 2003-2014 and find that there was no substantial effect on abuse treatment 
admissions when there was an operational PDMP in place. However, when there was a 
 
2 Misuse is defined as use for non-medical purposes  
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mandatory access provision, requiring providers to query the PDMP prior to prescribing a 
controlled drug, there was a significant reduction in prescription drug abuse with the main 
reduction shown in young adults aged 18-24.  
Existing economic literature on opioid antagonists has focused primarily on the impact 
they have on opioid overdoses. Rees, et. al., 2017 was the first study to examine the relationship 
between naloxone access laws and opioid-related deaths. Using cause-of-death mortality data 
from the National Vital Statistics System from the years 1999-2014, they found that the adoption 
of a NAL was associated with a 9 to 11% reduction in opioid-related deaths. After 2 years, the 
effect grew to an average of a 21% reduction in opioid deaths. This effect was apparent even 
after controlling for a Prescription Drug Monitoring Program. Their paper also focused on Good 
Samaritan Laws (GSLs), which prove immunity from prosecution for drug possession to anyone 
who seeks medical assistance in the event of an overdose.  The effect of GSLs on opioid-related 
deaths was comparable in magnitude to the NALs but was not statistically significant. 
I use insight gained from this paper to develop a hypothesis for the relationship between 
naloxone access laws and the type of referrals and treatment setting at admission at a treatment 
center for opioid abuse. 
3. Data and Methods 
This study utilizes individual-level data from the Treatment Episodes Data Set (TEDS)3 
that records the type of referrals and treatment settings of all the people admitted for treatment. 
 
3 U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, 
Center for Behavioral Health Statistics and Quality. (2018). National Survey on Drug Use and Health 2016 
(NSDUH-2016-DS0001). Retrieved from https://datafiles.samhsa.gov/ 
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This data is supplemented with state-level Naloxone Access Laws and related provisions from 
the Policy Surveillance Program (PSP).4Descriptions of each data source are below.  
3.1. Treatment Episodes Data Set 
I obtained individual-level data on substance abuse treatment from the TEDS. The first 
naloxone access law passed was in New Mexico in 2001. I concentrated on the period between 
1999 and 2015 to include a few years of the pre-adoption period. TEDS is a national data system 
maintained by the Center for Behavioral Health Statistics and Quality, Substance Abuse and 
Mental Health Services Administration (SAMSHA) that reports annual admissions to substance 
abuse treatment centers that receive funding from the state or federal government, are certified 
by the state to provide specialty substance abuse treatment, or are tracked for some other reason. 
This means that although TEDS is comprised of a significant portion of all admissions (about 
67% of the entire population of treatment admissions to all known providers), it doesn’t include 
all annual admissions nationwide. TEDS also doesn’t include data on facilities operated by the 
federal government (including, the Bureau of Prisons, the Department of Defense, and the 
Department of Veteran Affairs)  
It should also be noted that this feature has an important implication for interpreting my 
findings as the sample is composed of a disproportionate number of individuals who receive 
substance abuse treatment in a facility that is publicly funded. This leads to my data having a 
larger proportion of minority and lower income individuals. People with higher socio-economic 
status will generally attend more private treatment centers.  
 
4 Center for Public Health Law Research at the Temple University Beasley School of Law. Prescription Drug Abuse 
Policy System (PDAPS). (2018). Policy Surveillance Program. Retrieved from https://j.mp/2JrbffB  
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TEDS records admissions of those aged 12 and older and includes admission 
demographics such as age, sex, race, education, employment, etc. and substance abuse 
characteristics such as time of first use, substances used, number of prior admissions, etc.  
The primary units of observation are referral source and service setting at admission. The 
dataset includes self-referrals, referrals from the justice system, employers and educational 
agencies for the former, and includes 24-hour detox (inpatient and outpatient), rehab (short term, 
long term and hospital) and ambulatory (detoxification, non-intensive and intensive) for the 
latter. From these variables, I created two multinomial variables: referralsetting and 
adminsetting2, that range from 1-3. Referral source is broken up into three groups: individual 
referral, court/criminal justice referral and community referral. Admin setting is broken up into 
three groups: detox, rehab and ambulatory.  
3.2. Policy Surveillance Program 
The PSP is dedicated to increasing the use of policy surveillance and scientific legal 
mapping as tools for improving the nation’s health. The program addresses the chronic lack of 
readily accessible, non-partisan information about status and trends in health legislation and 
policy.  
Using the data from the PSP, I created six binary variables indicating: (1) whether the 
jurisdiction had a naloxone access law; (2) whether prescriptions of naloxone were authorized to 
third parties; (3) whether pharmacists allowed to dispense or distribute naloxone without a 
patient-specific prescription from another medical professional; (4) whether a layperson was 
immune from criminal liability when administering naloxone; (5) whether a layperson was 
immune from civil liability when administering naloxone and (6) whether the law removes 
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criminal liability for possession of naloxone without a prescription. I then merged this data with 
the TEDS variables.  
All models include time varying observable characteristics of the respondents such as 
age, education, and marital status. I included a series of indicator variables for the years 1999 to 
2015 to help capture some of the national trends such as the reformulation of OxyContin in 
2010.5 I also included a series of indicator variables for each core-based statistical area (cbsa) to 
capture geographical trends.6  
3.3. Empirical Model 
I estimate the relationship between naloxone access laws and types of referral and 
treatment service at admission using a multinomial (polytomous) logistic regression model. This 
model is employed when dependent variables involve three or more categories. Even though the 
categories are coded as 1, 2 and 3, there is no order to this (i.e. just because 1 < 2 < 3, it doesn’t 
imply that outcome 1 is less than outcome 2 is less than outcome 3). In a multinomial logit 
model, the coefficients estimated are 𝛽(1), 𝛽(2) and 𝛽(3). The multinomial logit model is outlined 














5 OxyContin was reformulated in 2010 to make the drug resistant to physical and chemical manipulation for abuse 
by snorting and injecting. It was approved by the FDA in 2011 but it did not meet the agency’s standard to be 
considered abuse-deterrent.  
6 A cbsa is a geographical area that consists of an urban center of at least 10,000 people plus adjacent counties that 
are socioeconomically tied to the urban center by commuting.  
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Since there are more than 2 categories, a baseline category needed to be determined. This 
is done by arbitrarily setting one of 𝛽(1), 𝛽(2) or 𝛽(3) to 0. See Equations (4) and (5) and (6) for 













There are two primary variables looked at: referralsource and adminsetting2, which are 
multinomial variables indicating the source of referral and the type of service and treatment 
setting in which the client is placed at the time of admission or transfer, respectively. These 
variables range from one to three. Referralsource is separated by individual, court/criminal 
justice, and community referrals (labeled 1, 2 and 3, respectively). Adminsetting2 is separated by 
detox, rehab, and ambulatory treatment settings (labeled 1, 2 and 3, respectively).  
Using the data from the PSP, I created 6 binary variables indicating whether there was a 
naloxone law passed in a given state s over year t and included five relevant provisions. 
Appendix Table 1 shows the effective dates of when the NAL and the relevant provisions were 
passed. I ran six separate regressions, one for the NAL indicator and one for each provision. 
Tables 3-9 show the results for the multinomial logit regressions. 
In all regressions, I control for a series of potentially confounding factors such as age, 
married, male, non-Hispanic black, Hispanic (white is omitted for multicollinearity) and 
education.  
All specifications include an indicator variable for cbsa, which control for any 
unmeasured heterogeneity across different geographic areas. Time fixed effects are also included 
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in all regressions, which capture unobserved trends in opioid use and related factors common to 
the entire population, such as the reformulation of oxycontin in 2010. 
4. Results 
4.1. Summary Statistics 
The data of admissions to treatment centers from 1999-2015 has 22,778,352 observations. 
After cleaning and merging with the data from the policy surveillance program, there are 
15,298,691 observations. I focused on a 20% random sample with a fixed seed so that the sample 
is replicable. Even with a 20% sample, there are over 4.5 million data entries. Table 2 includes 
descriptive statistics of the variables of interest in the dataset.  
TEDS includes data for persons aged 12 and over. Clients who are 11 or younger, or 
whose age is unknown, aren’t included in the data. Clients under 21 years of age were removed 
from the dataset. Clients between the ages 21-39 consist of a significant portion of all admissions 
(almost 63%) and as the age increases, the percentage of admission in the sample for that age 
group decreases. A significant majority of the admissions are composed of males, about 68%. 
The education group with the largest amount of admissions is 12 years (i.e. high school 
completion) consisting of almost 45% of all admissions. A majority of the referrals were self-
referrals and criminal/court system referrals (both totaling about 85% of all admissions). About 
65% of all admissions were ambulatory, which means that most of the clients were freely coming 
in and out of centers for treatment (i.e. weekly appointments, drug tests, check-ins).  
The results shown in this table are not surprising. As expected, the majority of the dataset 
consists of non-Hispanic white males. This is consistent with studies that show that the highest 
at-risk population for heroin addiction is non-Hispanic, white males. (Today’s Heroin Epidemic, 
2015). 
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Even though all states have passed some type of naloxone access law by 2017, only 
22.96% of the sample lived in states where there was a naloxone access law enacted. Since there 
has never been an event when one of the provisions was passed but no naloxone law was passed, 
it makes sense that the percentage of the sample living in states where a provision was passed is 
lower, for all provisions. 
Table 1 presents summary statistics for the variables of interest for the period preceding 
the naloxone access law and for the years after the law went into effect. Sample means for the 
demographic variables are similar among the treated and control groups with the exception of the 
amount of Hispanic people and the amount of married people. In NAL states, there were more 
Hispanic people admitted to treatment abuse centers and less married people.  
4.2.Regression Results 
Table 2 presents the estimated effects of NALs on referral source (relative to an 
individual referral) and on treatment setting at admission (relative to an ambulatory treatment 
setting). The results show that if there was a NAL enacted, the probability of being referred by a 
court/criminal justice system is 7.7% higher, relative to an individual referral and isn’t 
statistically significant at conventional levels. The probability of a community referral is 37.5% 
higher, relative to an individual referral and is statistically significant at the 5% level. If there 
was a NAL enacted, the probability of a detox setting at admission is 50% lower, relative to an 
ambulatory setting at admission and the probability of a rehab setting at admission is 14.5% 
higher, relative to an ambulatory setting. Both results are statistically significant at the 5% level.  
Table 3 presents the estimated effects of a third-party provision on referral source 
(relative to an individual referral) and on treatment setting at admission (relative to an 
ambulatory treatment setting). If there was a third-party provision enacted, the probability of 
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being referred by a court/criminal justice system is 6.8% higher, relative to an individual referral 
and is not statistically significant. The probability of a community referral is 39.4% higher, 
relative to an individual referral and is statistically significant at the 1% level. If there was a 
third-party provision enacted, the probability of a detox setting at admissions is 38.3% lower, 
relative to an ambulatory setting at admission and the probability of a rehab setting at admission 
is 5% higher, relative to an ambulatory setting at admission. Neither of these results are 
statistically significant.  
Table 4 presents the estimated effects of a pharmacist dispensing provision on referral 
source (relative to an individual referral) and on treatment setting at admission (relative to an 
ambulatory treatment setting). If there was a pharmacist dispensing provision enacted, the 
probability of being referred by a court/criminal justice system is 13.7% higher, relative to an 
individual referral and the probability of a community referral is 13.9% higher, relative to an 
individual referral. Neither of these results are statistically significant at conventional levels. If 
there was a pharmacist dispensing provision enacted, the probability of a detox setting at 
admission is 14.8% lower, relative to an ambulatory setting at admission and is not statistically 
significant. The probability of a rehab setting at admission is 20.4% higher, relative to an 
ambulatory setting and is significant at the 5% level.  
Table 5 presents the estimated effects of immunity from criminal liability for 
administration of naloxone provision on referral source (relative to an individual referral) and on 
treatment setting at admission (relative to an ambulatory treatment setting). If there was a 
criminal immunity for administration provision, the probability of being referred by a 
court/criminal justice system is 24.6% higher, relative to an individual referral and is statistically 
significant at the 5% level. The probability of a community referral is 19.2% higher, relative to 
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an individual referral and is not statistically significant. If there was a criminal immunity for 
administration provision, the probability of a detox setting at admission is 38% lower, relative to 
an ambulatory setting at admission and the probability of a rehab setting at admission is 5% 
higher, relative to an ambulatory setting. Neither of these results are statistically significant.  
Table 6 presents the estimated effects of an immunity from civil liability for 
administration of naloxone provision on referral source (relative to an individual referral) and on 
treatment setting at admission (relative to an ambulatory treatment setting). If there was a civil 
immunity for administration provision, the probability of being referred by a court/criminal 
justice system is 20.1% higher, relative to an individual referral and is not statistically 
significant. The probability of a community referral is 28.4% higher, relative to an individual 
referral and this result is statistically significant at the 5% levels. If there was a civil immunity 
for administration provision, the probability of a detox setting at admission is 54.5% lower, 
relative to an ambulatory setting at admission and is statistically significant at the 1% level. The 
probability of a rehab setting at admission is .1% higher, relative to an ambulatory setting and is 
not statistically significant.  
Table 7 presents the estimated effects of an immunity from criminal liability for 
possession of naloxone provision on referral source (relative to an individual referral) and on 
treatment setting at admission (relative to an ambulatory treatment setting). If there was a 
criminal immunity for possession provision, the probability of being referred by a court/criminal 
justice system is 17.7% higher, relative to an individual referral. The probability of a community 
referral is 28.4% lower, relative to an individual referral. If there was a criminal immunity for 
possession provision, the probability of a detox setting at admission is 16.3% higher, relative to 
an ambulatory setting at admission and the probability of rehab setting at admission is 4.3% 
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higher, relative to an ambulatory setting at admission. It is not surprising that none of these 
results are statistically significant at conventional levels as only 2.4% of the sample lived in 
states where there was a provision for immunity from criminal liability for possession of 
naloxone without a prescription. 
4.3.Regression Analysis 
Enacting a naloxone access law and/or a third-party provision significantly increases the 
probability of a community referral relative to an individual referral. States tend to discourage or 
even outright prohibit the prescription of drugs to a person who is not the intended recipient. By 
enacting a third-party provision and allowing people other than the drug user a prescription to 
naloxone, this significantly increases the probability of a community referral relative to an 
individual referral. Religious organizations, self-help groups dealing with addictions, and 
shelters will now be able to carry naloxone. These are the types of groups where people at risk 
for an opioid overdose tend to come to. These organizations can identify people at risk and if 
necessary, administer naloxone if someone is having an overdose. They can also urge the 
individual to get help and get them admitted to a treatment center.  
Some states have gone even further and enacted a civil liability provision, which gives 
immunity from civil prosecution for a layperson who administers naloxone. This leads to an 
increase in the probability of a community referral relative to an individual referral by 28.4%. By 
removing the possibility for civil prosecution for administering naloxone, the groups mentioned 
above have even more incentive to keep naloxone and administer when necessary. This provision 
also has an effect on the service setting at admission. 
Enacting a naloxone access law significantly decreases the probability of a detox setting 
at admission relative to an ambulatory setting, by 49.9%. Including a civil liability provision also 
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decreases the probability of a detox setting relative to an ambulatory setting decreases by over 
50%. This could be because now that naloxone is more accessible to the person who abuses 
opioids and their family and friends, it is less of a risk to allow the client to come in and out of 
the treatment center (ambulatory). While detox setting at admission might not decrease in 
general, it does in relation to ambulatory setting which could have increased with the passage of 
a NAL.  
The decrease could also be attributed to an increase in administrations done by 
laypersons rather than just trained medical professionals. It is easy to assume that there will be 
more administrations done by laypersons and not just trained medical professionals. Those who 
are saved from overdoses on opioids by laypersons are less likely to enter a detox program. More 
administrations of naloxone will occur at home or in other public settings instead of doctor 
offices, urgent cares or hospitals where that person would then be pushed to enter a detox 
program. This is not to say that treatment center admissions will decrease, just the type of setting 
at admission will be altered.  
Enacting a criminal liability provision significantly increases the probability of being 
referred to a treatment center by a court/criminal justice system, relative to an individual referral. 
Although naloxone is not a controlled substance, it is a prescription drug. People who are in 
possession of naloxone can administer it to a person having an overdose, can now summon 
emergency responders without fear of legal consequences. This provision removes the possibility 
of negative legal action against lay administration and in turn, leads to more court/criminal 
referrals to treatment admission centers.  
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5. Limitations 
When using the multinomial logit model, the maximum likelihood estimates of the 
coefficients may be biased if relevant variables have been left out of the specification. These 
omitted variables can be measured or unmeasured. Although I have included all variables which 
I thought relevant and that were provided in the dataset, there is always a possibility that there 
were variables that have been left out of the specification. Some individual level characteristics 
are missing from the dataset, such as income, employment and household characteristics 
(English not spoken at home, parents in the workforce, etc.).  
In the 2017 study examining the relationship between naloxone access laws and good 
Samaritan laws and opioid related deaths, Rees, et. al., include many environmental 
characteristics such as beer tax, cigarette tax, minimum wage, legalization of marijuana, etc. 
These could possibly have a significant effect if included in my specification. 
6. Conclusion 
In order to address the exponentially growing opioid epidemic in the United States, every 
state, the District of Columbia and even Puerto Rico (excluded from this study) have passed a 
naloxone law, allowing laypersons to administer naloxone to a person experiencing an overdose. 
The naloxone counteracts the effects of the overdose and restores breathing. Some states have 
gone even further and have passed provisions allowing prescriptions to third parties (i.e. friends 
and family of those at risk of an overdose), allowing pharmacists to distribute naloxone without a 
patient-specific prescription, giving civil and criminal immunity for administration of naloxone 
and/or possession of naloxone without a prescription.  
This study contributes on the effects of naloxone access laws and these provisions, 
specifically, on the source of referral (criminal/court and community, both relative to the 
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individual referral) and the type of treatment setting in which the client is placed at the time of 
admission or transfer (detox and rehab, both relative to an ambulatory setting).  
I found that passing a naloxone access law significantly increases the probability of a 
community referral relative to an individual referral. The law also decreases the probability of a 
detox setting at admission relative to an ambulatory setting at admission but increases the 
probability of a rehab setting at admission relative to an ambulatory setting. Including a third-
party provision significantly increases the probability of a community referral relative to an 
individual referral. Including a pharmacist dispensing provision increases the probability of a 
rehab setting at admission relative to an ambulatory setting. Including a criminal liability 
provision increases the probability of a criminal/court referral relative to an individual referral 
and increases the probability of a rehab setting at admission relative to an ambulatory setting at 
admission. Including a civil liability provision increases the probability of a community referral 
relative to an individual referral and decreases the probability of a detox setting at admission 
relative to an ambulatory setting.  
Naloxone has been supported by medical professionals and lawmakers alike for its ability 
to save lives from fatal opioid overdoses without medical consequences to the individual 
administering the drug. Although it is a prescription drug, there is no chance to develop a 
dependency on it and the side effects are minimal and not life threatening. The relevant laws 
passed in recent years have made the drug more accessible to people, both those who are at risk 
for an opioid overdose and those who are not. Laws have been passed to make sure laypersons 
who administer naloxone are immune from civil and/or criminal prosecution. As long as the 
price of naloxone does not continue to increase as it has been for the past few years, it will be a 
cost effective and accessible way to lower deaths from opioid overdoses.  
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Table One: Summary Statistics Pre and Post NAL 
 
 (1) (2) 
 Pre NAL Post NAL 
Age 21-24 0.15 0.14 
   
Age 25-29 0.17 0.18 
   
Age 30-34 0.16 0.16 
   
Age 35-39 0.15 0.12 
   
Age 40-44 0.14 0.12 
   
Age 45-49 0.11 0.12 
   
Age 50-54 0.06 0.09 
   
Age 55 and 
Over 
0.05 0.08 
   
Male 0.68 0.69 




   
Hispanic 0.09 0.16 
   
Married 0.19 0.15 
   
Less than High 
School 
0.06 0.07 








   
Some College 0.19 0.20 




   
* p < 0.05, ** p < 0.01, *** p < 0.001
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Table Two: 
Multinomial Logistic Regressions (Naloxone Access Law Treatment) 
 2 3 1 2 
NAL Treatment 1.077 1.375*** 0.501** 1.145** 
 (0.101) (0.143) (0.163) (0.074) 
Age 25-29 0.768*** 0.964* 1.192*** 1.075*** 
 (0.017) (0.020) (0.047) (0.025) 
Age 30-34 0.626*** 0.884*** 1.399*** 1.163*** 
 (0.017) (0.027) (0.081) (0.032) 
Age 35-39 0.555*** 0.809*** 1.636*** 1.229*** 
 (0.021) (0.036) (0.111) (0.039) 
Age 40-44 0.496*** 0.728*** 1.899*** 1.245*** 
 (0.025) (0.041) (0.146) (0.045) 
Age 45-49 0.451*** 0.689*** 2.076*** 1.218*** 
 (0.028) (0.049) (0.184) (0.047) 
Age 50-54 0.413*** 0.679*** 2.188*** 1.152*** 
 (0.030) (0.051) (0.221) (0.054) 
Age 55 and Over 0.416*** 0.625*** 2.070*** 1.037 
 (0.046) (0.056) (0.252) (0.070) 
Male 1.663*** 0.606*** 1.312*** 0.969 
 (0.061) (0.049) (0.086) (0.039) 
Non-Hispanic Black 1.193* 1.437*** 0.876** 1.070 
 (0.114) (0.160) (0.054) (0.071) 
Hispanic 1.307*** 1.259*** 0.943 0.824*** 
 (0.067) (0.067) (0.189) (0.051) 
Married 1.085** 0.967 0.597*** 0.703*** 
 (0.040) (0.071) (0.031) (0.027) 
Some High School 1.032 1.021 0.914 1.092*** 
 (0.055) (0.055) (0.073) (0.032) 
High School Completed 0.941 0.789*** 1.014 1.005 
 (0.054) (0.039) (0.068) (0.038) 
Some College 0.811** 0.663*** 1.017 1.040 
 (0.067) (0.047) (0.084) (0.047) 
College Completed 0.758* 0.555*** 1.032 1.082 
 (0.119) (0.061) (0.173) (0.106) 
 













Third Party Treatment 1.068 1.394*** 0.617 1.050 
 (0.114) (0.157) (0.206) (0.067) 
Age 25-29 0.768*** 0.964* 1.192*** 1.074*** 
 (0.017) (0.020) (0.047) (0.025) 
Age 30-34 0.626*** 0.884*** 1.401*** 1.162*** 
 (0.017) (0.027) (0.081) (0.032) 
Age 35-39 0.555*** 0.809*** 1.636*** 1.229*** 
 (0.021) (0.037) (0.111) (0.039) 
Age 40-44 0.496*** 0.729*** 1.894*** 1.246*** 
 (0.025) (0.041) (0.145) (0.045) 
Age 45-49 0.451*** 0.690*** 2.069*** 1.220*** 
 (0.028) (0.049) (0.183) (0.047) 
Age 50-54 0.413*** 0.680*** 2.180*** 1.153*** 
 (0.030) (0.051) (0.220) (0.054) 
Age 55 and Over 0.416*** 0.627*** 2.062*** 1.038 
 (0.046) (0.056) (0.251) (0.070) 
Male 1.664*** 0.606*** 1.309*** 0.970 
 (0.061) (0.049) (0.086) (0.039) 
Non-Hispanic Black 1.193* 1.439*** 0.873** 1.071 
 (0.114) (0.161) (0.055) (0.072) 
Hispanic 1.308*** 1.261*** 0.938 0.827*** 
 (0.067) (0.066) (0.188) (0.051) 
Married 1.085** 0.966 0.597*** 0.703*** 
 (0.040) (0.071) (0.031) (0.027) 
Some High School 1.032 1.023 0.911 1.092*** 
 (0.056) (0.056) (0.072) (0.033) 
High School Completed 0.941 0.790*** 1.010 1.005 
 (0.054) (0.039) (0.067) (0.038) 
Some College 0.812** 0.664*** 1.012 1.041 
 (0.067) (0.047) (0.084) (0.047) 
College Completed 0.759* 0.557*** 1.026 1.084 
 (0.119) (0.061) (0.171) (0.106) 
 
* p<0.1; ** p<0.05; *** p<0.01 
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Table Four: 









Pharm Disp. Treatment 1.137 1.139 0.852 1.204** 
 (0.151) (0.172) (0.266) (0.090) 
Age 25-29 0.768*** 0.963* 1.193*** 1.074*** 
 (0.017) (0.020) (0.047) (0.025) 
Age 30-34 0.626*** 0.883*** 1.403*** 1.163*** 
 (0.017) (0.026) (0.081) (0.032) 
Age 35-39 0.555*** 0.808*** 1.638*** 1.229*** 
 (0.021) (0.036) (0.111) (0.039) 
Age 40-44 0.496*** 0.730*** 1.891*** 1.247*** 
 (0.025) (0.041) (0.144) (0.045) 
Age 45-49 0.451*** 0.691*** 2.064*** 1.221*** 
 (0.028) (0.050) (0.182) (0.046) 
Age 50-54 0.413*** 0.681*** 2.175*** 1.155*** 
 (0.030) (0.052) (0.219) (0.054) 
Age 55 and Over 0.417*** 0.628*** 2.057*** 1.040 
 (0.046) (0.056) (0.251) (0.070) 
Male 1.665*** 0.608*** 1.305*** 0.971 
 (0.062) (0.050) (0.088) (0.040) 
Non-Hispanic Black 1.194* 1.443*** 0.871** 1.073 
 (0.115) (0.166) (0.056) (0.072) 
Hispanic 1.311*** 1.274*** 0.929 0.829*** 
 (0.069) (0.069) (0.191) (0.052) 
Married 1.085** 0.969 0.596*** 0.703*** 
 (0.040) (0.071) (0.030) (0.027) 
Some High School 1.033 1.023 0.915 1.093*** 
 (0.055) (0.055) (0.071) (0.033) 
High School Completed 0.941 0.789*** 1.015 1.006 
 (0.054) (0.039) (0.067) (0.038) 
Some College 0.813** 0.665*** 1.014 1.042 
 (0.067) (0.046) (0.083) (0.047) 
College Completed 0.759* 0.558*** 1.028 1.084 
 (0.119) (0.060) (0.171) (0.106) 
 













Crim Liability Treatment 1.246** 1.192 0.620 1.050 
 (0.139) (0.141) (0.205) (0.084) 
Age 25-29 0.768*** 0.963* 1.193*** 1.074*** 
 (0.017) (0.020) (0.047) (0.025) 
Age 30-34 0.626*** 0.883*** 1.402*** 1.162*** 
 (0.017) (0.026) (0.081) (0.032) 
Age 35-39 0.555*** 0.808*** 1.638*** 1.229*** 
 (0.021) (0.036) (0.111) (0.039) 
Age 40-44 0.496*** 0.730*** 1.892*** 1.246*** 
 (0.025) (0.041) (0.145) (0.045) 
Age 45-49 0.451*** 0.691*** 2.066*** 1.220*** 
 (0.028) (0.050) (0.183) (0.046) 
Age 50-54 0.413*** 0.681*** 2.177*** 1.154*** 
 (0.030) (0.052) (0.221) (0.053) 
Age 55 and Over 0.416*** 0.628*** 2.060*** 1.039 
 (0.046) (0.056) (0.253) (0.070) 
Male 1.665*** 0.609*** 1.305*** 0.970 
 (0.062) (0.050) (0.088) (0.040) 
Non-Hispanic Black 1.194* 1.443*** 0.871** 1.072 
 (0.115) (0.166) (0.055) (0.072) 
Hispanic 1.309*** 1.273*** 0.930 0.829*** 
 (0.069) (0.069) (0.191) (0.052) 
Married 1.085** 0.969 0.596*** 0.703*** 
 (0.040) (0.071) (0.030) (0.026) 
Some High School 1.031 1.022 0.917 1.092*** 
 (0.055) (0.055) (0.071) (0.033) 
High School Completed 0.940 0.789*** 1.017 1.005 
 (0.054) (0.039) (0.067) (0.038) 
Some College 0.812** 0.665*** 1.016 1.042 
 (0.067) (0.046) (0.083) (0.047) 
College Completed 0.758* 0.557*** 1.030 1.084 
 (0.119) (0.060) (0.172) (0.105) 
 













Civil Liability Treatment 1.201 1.284** 0.455*** 0.999 
 (0.168) (0.149) (0.139) (0.095) 
Age 25-29 0.768*** 0.963* 1.192*** 1.074*** 
 (0.017) (0.020) (0.047) (0.025) 
Age 30-34 0.626*** 0.883*** 1.402*** 1.162*** 
 (0.017) (0.026) (0.081) (0.032) 
Age 35-39 0.555*** 0.808*** 1.639*** 1.229*** 
 (0.021) (0.036) (0.110) (0.039) 
Age 40-44 0.496*** 0.730*** 1.891*** 1.246*** 
 (0.024) (0.041) (0.144) (0.045) 
Age 45-49 0.451*** 0.691*** 2.065*** 1.220*** 
 (0.028) (0.050) (0.183) (0.046) 
Age 50-54 0.413*** 0.681*** 2.179*** 1.154*** 
 (0.030) (0.052) (0.220) (0.054) 
Age 55 and Over 0.416*** 0.628*** 2.062*** 1.039 
 (0.046) (0.056) (0.254) (0.070) 
Male 1.665*** 0.608*** 1.305*** 0.971 
 (0.062) (0.050) (0.087) (0.040) 
Non-Hispanic Black 1.193* 1.442*** 0.873** 1.072 
 (0.115) (0.166) (0.056) (0.072) 
Hispanic 1.310*** 1.273*** 0.930 0.829*** 
 (0.069) (0.069) (0.192) (0.052) 
Married 1.085** 0.969 0.596*** 0.703*** 
 (0.040) (0.071) (0.030) (0.026) 
Some High School 1.031 1.022 0.922 1.092*** 
 (0.055) (0.054) (0.069) (0.033) 
High School Completed 0.940 0.788*** 1.023 1.005 
 (0.053) (0.039) (0.066) (0.038) 
Some College 0.811** 0.664*** 1.020 1.042 
 (0.067) (0.046) (0.081) (0.047) 
College Completed 0.758* 0.557*** 1.035 1.084 
 (0.119) (0.059) (0.171) (0.106) 
 













Crim Possession Treatment 1.177 0.716 1.163 1.043 
 (0.235) (0.165) (0.280) (0.142) 
Age 25-29 0.768*** 0.963* 1.193*** 1.074*** 
 (0.017) (0.020) (0.047) (0.025) 
Age 30-34 0.626*** 0.883*** 1.403*** 1.162*** 
 (0.017) (0.026) (0.081) (0.032) 
Age 35-39 0.554*** 0.807*** 1.639*** 1.229*** 
 (0.021) (0.036) (0.111) (0.039) 
Age 40-44 0.496*** 0.730*** 1.892*** 1.246*** 
 (0.025) (0.041) (0.144) (0.045) 
Age 45-49 0.451*** 0.691*** 2.065*** 1.220*** 
 (0.028) (0.050) (0.182) (0.046) 
Age 50-54 0.413*** 0.681*** 2.177*** 1.154*** 
 (0.030) (0.052) (0.219) (0.054) 
Age 55 and Over 0.416*** 0.628*** 2.060*** 1.039 
 (0.046) (0.056) (0.251) (0.070) 
Male 1.665*** 0.608*** 1.305*** 0.971 
 (0.062) (0.050) (0.087) (0.040) 
Non-Hispanic Black 1.194* 1.443*** 0.872** 1.072 
 (0.114) (0.166) (0.055) (0.072) 
Hispanic 1.312*** 1.273*** 0.930 0.828*** 
 (0.068) (0.069) (0.191) (0.052) 
Married 1.085** 0.969 0.596*** 0.703*** 
 (0.040) (0.071) (0.030) (0.026) 
Some High School 1.034 1.021 0.919 1.092*** 
 (0.058) (0.054) (0.070) (0.033) 
High School Completed 0.942 0.788*** 1.019 1.005 
 (0.055) (0.038) (0.066) (0.038) 
Some College 0.813** 0.664*** 1.017 1.042 
 (0.068) (0.046) (0.083) (0.047) 
College Completed 0.760* 0.558*** 1.030 1.084 
 (0.120) (0.059) (0.172) (0.106) 
 






Table One: Effective Dates of NALs and Provisions 
 
State NAL ThirdParty PharmDisp CrimLiab CivLiab CrimPoss 
AL 6/10/2015 6/10/2015 6/10/2015 6/10/2015 6/10/2015 - 
AK 3/15/2016 3/15/2016 3/15/2016 - 3/15/2016 - 
AZ 8/06/2016 8/06/2016 8/06/2016 - 8/06/2016 - 
AR 7/15/2015 7/15/2015 7/15/2015 7/15/2015 7/15/2015 - 
CA 1/01/2008 1/01/2014 1/01/2014 1/01/2011 1/01/2014 - 
CO 5/10/2013 4/03/2015 4/03/2015 5/10/2013 5/10/2013 - 
CT 10/01/2003 6/30/2015 6/30/2015 10/012003 10/012003 - 
DE 8/04/2014 - 8/04/2014 - - - 
DC 3/19/2013 2/18/2017 2/18/2017 3/19/2013 3/19/2013 3/19/2013 
FL 6/10/2015 6/10/2015 7/01/2016 - 6/10/2015 - 
GA 4/24/2014 4/24/2014 4/24/2014 4/24/2014 4/24/2014 - 
HI 6/16/2016 6/16/2016 6/16/2016 6/16/2016 6/16/2016 6/16/2016 
ID 7/01/2015 7/01/2015 7/01/2015 7/01/2015 7/01/2015 - 
IL 1/01/2010 1/01/2010 1/01/2010 1/01/2010 9/09/2015 - 
IN 04/17/2015 04/17/2015 04/17/2015 - 04/17/2015 - 
IA 5/27/2016 5/27/2016 5/27/2016 - 5/27/2016 5/27/2016 
KS 7/01/2017 - 7/01/2017 7/01/2017 7/01/2017 - 
KY 6/25/2013 6/25/2013 6/25/2013 6/25/2013 6/25/2013 - 
LA 8/15/2015 8/15/2015 8/15/2015 8/15/2015 8/15/2015 6/06/2016 
ME 4/29/2014 4/29/2014 10/15/2015 7/29/2016 7/29/2016 - 
MD 10/1/2013 10/01/2013 10/01/2015 - 10/01/2015 - 
MA 8/02/2012 8/02/2012 7/01/2014 7/01/2014 3/12/2016 8/02/2012 
MI 10/14/2014 10/14/2014 3/28/2017 10/14/2014 10/14/2014 10/14/2014 
MN 5/10/2014 - 5/10/2014 5/10/2014 5/10/2014 - 
MS 7/01/2015 7/01/2015 7/01/2015 7/01/2015 7/01/2015 - 
MO 8/28/2016 - 8/28/2016 8/28/2016 8/28/2016 8/28/2016 
MT 5/03/2017 5/03/2017 5/03/2017 5/03/2017 5/03/2017 - 
NE 5/28/2015 5/28/2015 - 5/28/2015 - - 
NV 10/01/2015 10/01/2015 10/01/2015 10/01/2015 10/01/2015 10/01/2015 
NH 6/02/2015 6/02/2015 6/02/2015 6/02/2015 6/02/2015 - 
NJ 7/01/2013 7/01/2013 7/01/2013 7/01/2013 7/01/2013 - 
NM 4/03/2001 4/03/2001 3/14/2014 9/13/2001 9/13/2001 3/04/2016 
NY 4/01/2006 2/01/2007 6/24/2014 6/24/2014 6/24/2014 - 
NC 4/09/2013 4/09/2013 4/09/2013 4/09/2013 4/09/2013 - 
ND 8/01/2015 8/01/2015 8/01/2015 8/01/2015 8/01/2015 8/01/2015 
OH 3/11/2014 3/11/2014 3/11/2014 3/11/2014 - - 
OK 11/01/2013 11/01/2013 11/01/2014 - - - 
OR 6/06/2013 8/06/2013 6/06/2013 - 6/06/2013 - 
PA 12/01/2014 12/01/2014 12/01/2014 12/01/2014 12/01/2014 - 
RI 6/18/2012 3/03/2014 3/03/2014 6/18/2012 6/18/2012 3/03/2014 
30 
SC 6/03/2015 6/03/2015 6/03/2015 6/03/2015 6/03/2015 - 
SD 7/01/2016 7/01/2016 7/01/2016 - - - 
TN 7/01/2014 7/01/2014 7/01/2014 - 7/01/2014 - 
TX 9/01/2015 9/01/2015 9/01/2015 9/01/2015 9/01/2015 9/01/2015 
UT 5/13/2014 5/13/2014 5/10/2016 - 5/13/2014 - 
VT 7/01/2013 7/01/2013 7/01/2013 7/01/2013 7/01/2013 7/01/2013 
VA 7/01/2013 7/01/2013 4/15/2015 - 7/01/2013 - 
WA 6/10/2010 6/10/2010 7/24/2015 6/10/2010 7/24/2015 - 
WV 5/27/2015 5/27/2015 7/24/2015 6/10/2016 5/27/2015 5/27/2015 
WI 4/09/2014 4/09/2014 4/09/2014 4/09/2014 4/09/2014 4/09/2014 
WY 7/01/2017 7/01/2017 7/01/2017 7/01/2017 7/01/2017 - 
 
